BMO Capital Markets Boosts Johnson & Johnson (JNJ) Price Target to $161.00
Johnson & Johnson (NYSE:JNJ) had its price target hoisted by stock analysts at BMO Capital Markets to $161.00 in a report released on Tuesday. The brokerage presently has an “outperform” rating on the stock. BMO Capital Markets’ target price indicates a potential upside of 12.45% from the stock’s previous close.
Several other research analysts have also recently issued reports on JNJ. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday. J P Morgan Chase & Co increased their price objective on shares of Johnson & Johnson from $140.00 to $148.00 and gave the company an “overweight” rating in a report on Wednesday, August 16th. Jefferies Group set a $145.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a report on Tuesday, August 15th. Citigroup began coverage on shares of Johnson & Johnson in a report on Monday, September 25th. They issued a “neutral” rating and a $140.00 price objective for the company. Finally, Royal Bank of Canada increased their price objective on shares of Johnson & Johnson from $144.00 to $147.00 and gave the company an “outperform” rating in a report on Wednesday, October 18th. Four analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Johnson & Johnson currently has an average rating of “Hold” and an average price target of $145.04.
Johnson & Johnson (NYSE JNJ) traded up $2.04 during trading on Tuesday, hitting $143.18. 3,780,000 shares of the stock traded hands, compared to its average volume of 4,770,000. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $384,670.00, a PE ratio of 19.69, a PEG ratio of 2.86 and a beta of 0.80. Johnson & Johnson has a twelve month low of $110.76 and a twelve month high of $144.35.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.80 by $0.10. The business had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the firm posted $1.68 earnings per share. equities research analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current year.
Several large investors have recently modified their holdings of the stock. Karpus Management Inc. purchased a new stake in Johnson & Johnson in the 3rd quarter worth approximately $231,000. Wagner Bowman Management Corp lifted its position in Johnson & Johnson by 3.2% in the 3rd quarter. Wagner Bowman Management Corp now owns 47,171 shares of the company’s stock worth $6,132,000 after buying an additional 1,452 shares in the last quarter. Hikari Tsushin Inc. lifted its position in Johnson & Johnson by 8.3% in the 3rd quarter. Hikari Tsushin Inc. now owns 53,810 shares of the company’s stock worth $6,996,000 after buying an additional 4,130 shares in the last quarter. Burgundy Asset Management Ltd. lifted its position in Johnson & Johnson by 0.4% in the 3rd quarter. Burgundy Asset Management Ltd. now owns 3,195,878 shares of the company’s stock worth $415,496,000 after buying an additional 11,257 shares in the last quarter. Finally, Chicago Partners Investment Group LLC lifted its position in Johnson & Johnson by 9.9% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 12,714 shares of the company’s stock worth $1,653,000 after buying an additional 1,144 shares in the last quarter. Institutional investors and hedge funds own 65.89% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.